Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 121-125

  Turaka, Kiran ^a   Shields, Carol L ^a   Meadows, Anna T ^b   Leahey, Ann ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute promyelocytic leukemia; Chemoreduction; External beam radiotherapy; Osteosarcoma; Retinoblastoma; Rhabdomyosarcoma; Second cancers

Indexed keywords

CARBOPLATIN; ETOPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AFRICAN AMERICAN; ARTICLE; ASIAN; BLASTOMA; CANCER CHEMOTHERAPY; CANCER RISK; CAUCASIAN; CHILD; CONJUNCTIVA TUMOR; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENETIC SCREENING; GLIOMA; HISPANIC; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; ORBIT TUMOR; OSTEOSARCOMA; PINEOBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETINOBLASTOMA; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SCHOOL CHILD; TRANSPUPILLARY THERMOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; EYE NEOPLASMS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; NEOPLASMS, SECOND PRIMARY; RETINOBLASTOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 84861214968     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23278     Document Type: Article

References (35)

1. Shields C, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17: 228-234.
2. Schefler AC, Abramson DH. Retinoblastoma: What is new in 2007-2008. Curr Opin Ophthalmol 2008; 19: 526-534.
3. Meadows AT, Shields CL. Regarding chemoreduction for retinoblastoma and intracranial neoplasms. Arch Ophthalmol 2004; 122: 1570-1571.
4. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996; 2: 1499-1508.
5. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113: 2276-2280.
6. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 2005; 23: 2272-2279.
7. Abramson DH, Jereb B, Ellsworth RM. External beam radiotherapy for retinoblastoma. Bull NY Acad Med 1981; 57: 787-803.
8. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99: 24-31.
9. Wong FL, Boice JD, Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278: 1262-1267.
10. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85: 1121-1128.
11. MacCarthy A, Bayne AM, Draper GJ, et al. Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. Br J Ophthalmol 2009; 93: 1159-1162.
12. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96: 357-363.
13. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986; 53: 661-671.
14. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with hereditary retinoblastoma: A register-based follow-up study, 1945-1994. Int J Cancer 1996; 67: 515-519.
15. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma more than 40 years of follow-up. J Natl Cancer Inst 2008; 100: 1771-1779.
16. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52: 637-643.
17. Lambert MP, Shields CL, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008; 50: 223-226.
18. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor? Ophthalmology 2007; 114: 1378-1383.
19. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in 5-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93: 618-629.
20. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007; 109: 46-51.
21. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101: 581-591.
22. Shields CL, DePotter P, Himmelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1330-1338.
23. Murphree AL, Villablanca JG, Deegan WF III, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1348-1356.
24. Dunkel IJ, Lee TC, Shi W, et al. A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer 2007; 49: 643-648.
25. Beck MN, Balmer A, Dessing C, et al. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000; 18: 2881-2887.
26. Lumbrusso L, Doz F, Urbieta M, et al. Chemotherapy in the management of retinoblastoma. Ophthalmology 2002; 109: 1130-1136.
27. Zage PE, Reitman AJ, Seshadri R, et al. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer 2008; 50: 567-572.
28. Strong LC, Knudson AG, Jr. Letter: Second cancer in retinoblastoma. Lancet 1973; 2: 1086.
29. Pedersen-Bjergaard J, Rowley J. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
30. Smith M, Rubinstein L, Ungerleider R. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 1994; 23: 86-98.
31. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17: 569-577.
32. Rihani R, Bazzeh F, Faqih N, et al. Secondary hematopoietic malignancies in survivors of childhood cancer. Cancer 2010; 116: 4385-4394.
33. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006; 15: 2020-2026.
34. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351-357.
35. Ahuja HG, Jat PS, Foti A, et al. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78: 3259-3268.